C Franzese1, A Fogliata2, G R D'Agostino1, L Di Brina1, T Comito1, P Navarria1, L Cozzi1,3, M Scorsetti1,3. 1. Radiotherapy and Radiosurgery Department, Humanitas Research Hospital and Cancer Center, Milan-Rozzano, Italy. 2. Radiotherapy and Radiosurgery Department, Humanitas Research Hospital and Cancer Center, Milan-Rozzano, Italy. antonella.fogliata@humanitas.it. 3. Department of Biomedical Science, Humanitas University, Milan-Rozzano, Italy.
Abstract
PURPOSE: The optimal treatment for unfavourable intermediate/high-risk prostate cancer is still debated. In the present study, the pattern of toxicity and early clinical outcome of patients with localized prostate cancer was analyzed. METHODS: A cohort of 90 patients treated on pelvic lymph nodes from 2010 to 2015 was selected. All patients were treated with Volumetric Modulated Arc Therapy (VMAT), and Simultaneous integrated boost (SIB) in 28 fractions; the prostate, the seminal vesicle and the pelvic lymph node received total doses of 74.2, 65.5, and 51.8 Gy, respectively. End points were the detection of acute and late toxicities graded according to the Common Toxicity Criteria CTCAE version 3, evaluating the rectal, genito-urinary and gastro-intestinal toxicity. Correlation of OARs dose parameters and related toxicities was explored. Preliminary overall survival and Progression-free survival (PFS) were evaluated. RESULTS: With a median follow-up of 25 months, no interruptions for treatment-related toxicity were recorded. Univariate analysis among dosimetric data and acute toxicities showed no correlations. Regarding late toxicity: the dose received by a rectal volume of 90 cm3 was found to be significant for toxicity prediction (p = 0.024). PFS was 90.6% and 60.2% at 2 and 4 years, respectively. PFS correlates with age (p = 0.011) and Gleason score (p = 0.011). Stratifying the PSA nadir in quartiles, its value was significant (p = 0.016) in predicting PFS, showing a reduction of PFS of 2 months for each PSA-nadir increase of 0.1 ng/ml. CONCLUSION: HRT with VMAT and SIB on the whole pelvis in unfavourable prostate cancer patients is effective with a mild pattern of toxicity.
PURPOSE: The optimal treatment for unfavourable intermediate/high-risk prostate cancer is still debated. In the present study, the pattern of toxicity and early clinical outcome of patients with localized prostate cancer was analyzed. METHODS: A cohort of 90 patients treated on pelvic lymph nodes from 2010 to 2015 was selected. All patients were treated with Volumetric Modulated Arc Therapy (VMAT), and Simultaneous integrated boost (SIB) in 28 fractions; the prostate, the seminal vesicle and the pelvic lymph node received total doses of 74.2, 65.5, and 51.8 Gy, respectively. End points were the detection of acute and late toxicities graded according to the Common Toxicity Criteria CTCAE version 3, evaluating the rectal, genito-urinary and gastro-intestinal toxicity. Correlation of OARs dose parameters and related toxicities was explored. Preliminary overall survival and Progression-free survival (PFS) were evaluated. RESULTS: With a median follow-up of 25 months, no interruptions for treatment-related toxicity were recorded. Univariate analysis among dosimetric data and acute toxicities showed no correlations. Regarding late toxicity: the dose received by a rectal volume of 90 cm3 was found to be significant for toxicity prediction (p = 0.024). PFS was 90.6% and 60.2% at 2 and 4 years, respectively. PFS correlates with age (p = 0.011) and Gleason score (p = 0.011). Stratifying the PSA nadir in quartiles, its value was significant (p = 0.016) in predicting PFS, showing a reduction of PFS of 2 months for each PSA-nadir increase of 0.1 ng/ml. CONCLUSION: HRT with VMAT and SIB on the whole pelvis in unfavourable prostate cancerpatients is effective with a mild pattern of toxicity.
Authors: Daniel A Hamstra; Kyounghwa Bae; Miljenko V Pilepich; Gerald E Hanks; David J Grignon; David G McGowan; Mack Roach; Colleen Lawton; R Jeffrey Lee; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2011-03-31 Impact factor: 7.038
Authors: Nadeem Pervez; Cormac Small; Marc MacKenzie; Don Yee; Matthew Parliament; Sunita Ghosh; Alina Mihai; John Amanie; Albert Murtha; Colin Field; David Murray; Gino Fallone; Robert Pearcey Journal: Int J Radiat Oncol Biol Phys Date: 2010-01-01 Impact factor: 7.038
Authors: Alan Pollack; Gail Walker; Eric M Horwitz; Robert Price; Steven Feigenberg; Andre A Konski; Radka Stoyanova; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; Charlie Ma; Mark K Buyyounouski Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Hans T Chung; Ping Xia; Linda W Chan; Eileen Park-Somers; Mack Roach Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-22 Impact factor: 7.038
Authors: Roman Ganzer; Johannes Bründl; Daniel Koch; Wolf F Wieland; Maximilian Burger; Andreas Blana Journal: World J Urol Date: 2014-04-03 Impact factor: 4.226
Authors: Dalia Ahmad Khalil; Danny Jazmati; Dirk Geismar; Jörg Wulff; Christian Bäumer; Paul Heinz Kramer; Theresa Steinmeier; Stefanie Schulze Schleitthoff; Sandija Plaude; Martin Bischoff; Stephan Tschirdewahn; Boris Hadaschik; Beate Timmermann Journal: Radiat Oncol Date: 2022-04-01 Impact factor: 3.481
Authors: Luca Cozzi; Antonella Fogliata; Stephen Thompson; Ciro Franzese; Davide Franceschini; Fiorenza de Rose; Stefano Tomatis; Marta Scorsetti Journal: Technol Cancer Res Treat Date: 2018-01-01